Drug Approval | May 15, 2022
USFDA approves novel, dual-targeted treatment for type 2 diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
In clinical trials, treatment proved more effective than other therapies evaluated
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Subscribe To Our Newsletter & Stay Updated
